<DOC>
	<DOCNO>NCT00733538</DOCNO>
	<brief_summary>- Assessment survival without progression stage I MM two group : arm A : simple survey arm B : administration Zoledronate . - Describe different progression 's type notice define prognosis factor fast evolution .</brief_summary>
	<brief_title>Stage I Multiple Myeloma Treatment</brief_title>
	<detailed_description>RATIONAL : Multiple Myeloma spite therapy progress mainly due stem cell auto transplant , still remain deadly disease . About 2000 new case diagnose every year France . The asymptomatic Stage I MM accord Duries Salmon 's stag usually watch treated progression . Zoledronate third generation aminobiphosphonate ( BP ) , probably powerful among available compound receive market clearance authorisation MM bone damage . During MM , bone 's hyper resorption premature . Interactions exist tumor growth bone lyses . Zoledronate 's get proper antimyeloma 's action ( induce plasma cell apoptosis ) . We propose test early use Zoledronate soon stage I MM delay progression . STUDY 'S OBJECTIVES : - PRINCIPAL : Assessment survival without progression stage I MM two group : A arm : simple survey B arm : administration BP . - SECONDARY : Describe different progression 's type notice ( bone/extra bone ) define prognosis factor fast stage I MM evolution ( standard factor , cytogenetic 13 deletion , bone 's restructuring strain : crosslaps , bone alkaline phosphatase ) , list side effect . STUDY 'S KIND : Multicenter international randomise trial , open label , individual profit . CONTRIBUTING CENTERS : Intergroupe Francophone du My√©lome 's center . INCLUSIONS CRITERIA : Asymptomatic stage I MM without bone 's lesion standard radiograph . STUDY 'S MONITORING : After check inclusion non inclusion specification , patient include study randomize ( A arm B arm ) treatment . The randomisation do center stratify accord diagnostic date witch year . - Arm A : simple survey standard practice . - Arm B : 15 minute infusion Zoledronate every month progression maximum 18 infusion progression . The exams one usually define accord good clinical practice guideline besides cytogenetic , bone 's restructuring strain serum creatin dosage infusion B arm . STATISTICAL PURPOSES : The minimum number patient require show median survival time increase without progression 26 month control arm 38 month BP arm 175 patient arm 48 month inclusion 's period , monitor 24 month last inclusion ( i.e . study 's length 6 year ) .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<criteria>stage I multiple myeloma without bone injury abnormal kidney function VIH infection Hepatic incapacity pregnancy Associate pathology</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>stage I multiple myeloma</keyword>
</DOC>